An open label, single arm, phase II study to evaluate the activity and toxicity of Panitumumab in pre-treated patients with advanced well differentiated neuroendocrine tumor (G1 and G2)

Trial Profile

An open label, single arm, phase II study to evaluate the activity and toxicity of Panitumumab in pre-treated patients with advanced well differentiated neuroendocrine tumor (G1 and G2)

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2015

At a glance

  • Drugs Panitumumab (Primary)
  • Indications Neuroendocrine tumours
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 14 Nov 2015 Status changed from discontinued to completed as reported by European Clinical Trials Database record.
    • 19 Sep 2015 Status changed from recruiting to discontinued, according to European Clinical Trials Database record.
    • 19 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top